Inhibitor Therapeutics, Inc. has filed a Current Report on Form 8-K with the Securities and Exchange Commission, detailing a significant development regarding its financing arrangements. The company reported that it entered into a Securities Purchase Agreement (SPA) with an institutional investor on February 24, 2026, which involved the sale of 12 million shares of its common stock at a price of $0.25 per share, along with a warrant for an additional 7 million shares. However, the investor failed to fulfill its obligations under the SPA, prompting Inhibitor Therapeutics to initiate litigation on March 30, 2026. This legal action follows multiple attempts by the company to secure the necessary funding of $3 million from the investor without resorting to litigation. The company plans to provide further details regarding the litigation in a subsequent report. This situation raises concerns about the company's liquidity and operational execution, as the failure to secure funding could impact its ongoing projects and financial stability.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.